Ociperlimab

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Lung CancerAdvanced Malignancies

199 competitors in Lung Cancer

#DrugCompanyPhaseTrials

1

Keytruda

Merck & Co.

Phase 3

322

Imfinzi

AstraZeneca

Phase 3

253

Opdivo

Bristol-Myers Squibb

Phase 3

204

Tagrisso

AstraZeneca

Phase 3

175

Beyfortus

BeiGene

Phase 3

106

Yervoy

Bristol-Myers Squibb

Phase 3

107

Abraxane

Bristol-Myers Squibb

Phase 3

78

Imjudo

AstraZeneca

Phase 3

69

Tecentriq

Roche

Phase 3

610

Alunbrig

Takeda

Phase 3

4Show 34 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer3 trials

A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer

Terminated·BeiGene·Phase 3·NCT04866017·63 enrolled

Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer

Completed·BeiGene·Phase 2·NCT05577702·121 enrolled

Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer

Completed·BeiGene·Phase 2·NCT05014815·272 enrolled

Advanced Solid Tumors1 trial

Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors

Completed·BeiGene·Phase 1·NCT04047862·446 enrolled

Efficacy and Safety1 trial

A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC

Completed·BeiGene·Phase 2·NCT04948697·94 enrolled

Esophageal Squamous Cell Carcinoma1 trial

Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Completed·BeiGene·Phase 2·NCT04732494·125 enrolled

Small Cell Lung Cancer1 trial

Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer

Completed·BeiGene·Phase 2·NCT04952597·126 enrolled

6 more indications

Lung Cancer1 trial

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

Active, not recruiting·BeiGene·Phase 3·NCT04746924·662 enrolled

Advanced Malignancies1 trial

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

Enrolling by invitation·BBeOne Medicines·Phase 3·NCT04164199·430 enrolled

Locally Advanced or Metastatic NSCLC1 trial

Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC.

Withdrawn·Novartis·Phase 3·NCT05791097

Lymphoma1 trial

Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab

Completed·BeiGene·Phase 1/2·NCT05267054·53 enrolled

Cervical Cancer1 trial

AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer

Completed·BeiGene·Phase 2·NCT04693234·178 enrolled

Breast Cancer1 trial

Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer

Withdrawn·Novartis·Phase 2·NCT05809895

Details

Drug Info

Related News